Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis.

BACKGROUND: Clinical benefit of paclitaxel-coated devices for patients with peripheral arterial disease has been confirmed in randomized controlled trials (RCTs). A meta-analysis published in 2018 identified late mortality risk over a long follow-up period due to use of paclitaxel-coated devices in the femoropopliteal arteries, which caused enormous controversy and debates globally. This study aims to further evaluate the safety of paclitaxel-coated devices by incorporating the most recently published data.
METHODS: We searched for candidate studies in PubMed (MEDLINE), Scopus, EMBASE (Ovid) online databases, government web archives and international cardiovascular conferences. Safety endpoints of interest included all-cause mortality rates at one, two and five years and the risk ratio (RR) was used as the summary measure. The primary analysis was performed using random-effects models to account for potential clinical heterogeneity.
FINDINGS: Thirty-nine RCTs including 9164 patients were identified. At one year, the random-effects model yielded a pooled RR of 1.06 (95% CI [0.87, 1.29]) indicating no difference in short-term all-cause deaths between the paclitaxel and control groups (crude mortality, 4.3%, 214/5025 versus 4.5%, 177/3965). Two-year mortality was reported in 26 RCTs with 382 deaths out of 3788 patients (10.1%) in the paclitaxel arm and 299 out of 2955 patients (10.1%) in the control arm and no association was found between increased risk of death and usage of paclitaxel-coated devices (RR 1.08, 95% CI [0.93, 1.25]). Eight RCTs recorded all-cause deaths up to five years and a pooled RR of 1.18 (95% CI [0.92, 1.51]) demonstrated no late mortality risk due to use of paclitaxel-coated devices (crude mortality, paclitaxel 18.2%, 247/1360 versus control 15.2%, 122/805).
CONCLUSIONS: We found no significant difference in either short- or long-term all-cause mortalities between patients receiving paclitaxel-coated and uncoated devices. Further research on the longer-term safety of paclitaxel usage (e.g., 8- or 10-year) is warranted. REGISTRATION: PROSPERO, CRD42021246291.

Introduction

Peripheral arterial disease (PAD) is a common cardiovascular disease which affects about 10% of the general population worldwide [1]. PAD is known as one of the leading causes of cardiovascular morbidity and mortality and the progressed PAD can result in severe impairment of functional capacity and deterioration of life quality [2] Standard percutaneous transluminal angioplasty (PTA) has been used as the first line endovascular therapy for the treatment of PAD but is associated with a high rate of vessel restenosis and limited durability in clinical efficacy [3]. In recent years, the newly developed drug-coated balloons (DCBs) and drug-eluting stents (DESs) using paclitaxel in the femoropopliteal arteries (FPAs) have shown substantial improvements in reducing restenosis, target lesion revascularization and late lumen loss [4-6].

However, the safety of long-term use of paclitaxel DCB and DES has raised great concerns. In December 2018, Katsanos et al. [7] demonstrated the association between the use of paclitaxel DCB or DES and increased long-term risk of all-cause deaths compared with PTA or bare metal stent (BMS) in their meta-analysis with 28 randomized controlled trials (RCTs). As a result, the U.S. Food and Drug Administration (FDA) issued warning letters to health care providers regarding potential risk of paclitaxel devices [8, 9] and a preliminary analysis conducted by FDA reported an approximately 50% increase in all-cause mortality for patients treated with paclitaxel-coated devices versus control [9].

The SWEDEPAD [10] and BASIL-3 [11] trials, which investigated paclitaxel-coated devices in patients with PAD, were both temporarily suspended in December 2018 due to concerns on patient safety. The BASIL-3 trial restarted patient enrollment in September 2019 according to recommendations from an independent expert advisory group [12]. An unplanned interim analysis of the SWEDEPAD trial [10] showed no difference in mortality between the paclitaxel-coated and uncoated groups at one year or during the entire follow-up period thus far, and based on these results, it was decided to resume enrollment in the SWEDEPAD trial in March 2020. Such conflicting evidence led to further controversy over risks and benefits of paclitaxel-used devices for the treatment of PAD [13].

We conducted this systematic review and meta-analysis to update findings from previous reports by including more recently published RCTs and explore short- and long-term safety issues of paclitaxel DCBs or DESs in the FPAs.

Methods

This systematic review and meta-analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14] and registered in the PROSPERO database (CRD42021246291; https://www.crd.york.ac.uk/prospero/).

Study selection

We performed extensive online searches of the PubMed (MEDLINE), Scopus, EMBASE (Ovid) databases, government web archives (US Food and Drug Administration and European Medicines Agency) and oral presentations in international cardiovascular conferences for eligible studies from August 2018 to June 2022. Our analysis also included 28 RCTs investigated in Katasanos et al. [7], for which the literature search was up to August 2018. There were no restrictions on publication language or publication status. The detailed searching strategies were given in S1 Table.

We included studies which met the following inclusion criteria: (1) randomized controlled trial; (2) patients with peripheral arterial disease of the FPA; (3) head-to-head comparison between paclitaxel-coated/eluting balloons/stents and standard percutaneous transluminal angioplasty or bare metal stent; (4) follow-up period ≥1 year; (5) outcome measures of interest reported. The exclusion criteria were: (1) retrospective cohort study or non-randomized trial; (2) treatment in vessels other than FPA; (3) studies that compared paclitaxel-coated/eluting devices with other drug-coated/eluting devices.

Data extraction and assessment of risk of bias

Assessment of eligible studies and data extraction were performed by two investigators separately and they resolved disagreements by discussion. Titles and abstracts (if available) of studies were reviewed and full texts of those meeting the inclusion criteria were further screened for eligibility. For each included trial, we collected information of the trial design, paclitaxel DCB and DES devices used in the intervention, baseline demographic characteristics and outcome measures of interest.

Two independent reviewers evaluated the quality of included RCTs using a revised Cochrane risk-of-bias tool for randomized trials (RoB 2.0) [15], which focuses on five domains of bias: bias arising from the randomization process; bias due to deviations from intended interventions; bias due to missing outcome data; bias in measurement of the outcome; and bias in selection of the reported results. Any discrepancies were resolved by discussion.

Outcome measurement

In this meta-analysis, we focused on all-cause mortality at one year, two years and five years as safety endpoints to evaluate short- and long-term risks of paclitaxel-coated/eluting devices in the FPAs. If there were several studies (e.g., interim analysis) reporting the same trial, results extracted from the latest one were considered for quantitative analysis.

Statistical analyses

The primary analysis investigated the number of all-cause deaths at several prespecified time points, for which the risk ratio (RR) with the corresponding 95% confidence interval (CI) was used as the summary measure. The pooled estimates were calculated by the random-effects model to account for heterogeneity due to differences in trial designs, use of paclitaxel devices and patient populations. The Mantel-Haenszel fixed-effects model and Bayesian meta-analysis under the binomial-logit framework were conducted as sensitivity analyses. The potential publication bias was visually evaluated by checking asymmetry of funnel plots [16] and statistically examined by Egger’s test [17].

Subgroup analyses were conducted to assess the influence of paclitaxel dose levels and types of paclitaxel-coated devices on patient mortality rates. We also performed a meta-regression analysis under the Bayesian binomial-logit model using the proportion of patients with chronic limb threatening ischemia (CLTI) in each arm as the covariate. Enrolled patients suffering from PAD consisted of those with CLTI and those with intermittent claudication (IC). Compared with IC, CLTI is an advanced stage of PAD with higher amputation and mortality rates [18] and might be one potential cause of heterogeneity among studies. All statistical analyses were performed using the R language version 4.0.3 (RStudio, Boston, MA) with the ‘meta’ package for frequentist meta-analysis and ‘jagsUI’ package for Bayesian meta-analysis and meta-regression.

Results

The online search from databases and other sources identified 1384 publications based on the prespecified search strategy after deleting duplicate records, of which 1237 studies were excluded after screening titles and abstracts. Full texts of the remaining 147 articles/presentations were assessed for eligibility and 59 of them were qualified for inclusion in the systematic review and meta-analysis. The flow diagram of our study selection process is shown in Fig 1.

Fig 1

Flow diagram of study selection.

Overall, the selected 59 studies reported 39 unique RCTs including 9164 patients [6, 10, 19–75]. The design characteristics of eligible RCTs are provided in Table 1. Out of these 39 RCTs, 29 RCTs investigated the clinical effectiveness of paclitaxel DCB, four tested the paclitaxel-coated balloon in combination with a BMS and the other six were for DES. Almost all studies evaluated the performance of one single paclitaxel device at the nominal paclitaxel dose of 2.0 (7/39), 3.0 (21/39) and 3.5 μg/mm2 (9/39) except the SWEDEPAD trial [10] in which multiple device brands were used at various dose levels. Thirty RCTs were conducted at multiple sites, three were two-center and six were single-center. Three RCTs were double-blinded to both patients and investigators for the treatment allocation, 24 were single-blinded to patients only and the other 12 were open-label studies.

Table 1

Study characteristics of the 39 included randomized controlled trials in the meta-analysis.

Trial	Registration Number	Follow-up	Study Design	Location	Treatment	Control	Sample size, Intervention	Sample size, Control	Paclitaxel-Coated Device	Dose (μg/mm2)
ZILVER-PTX [40, 59, 71]	NCT00120406	5	Multi-center; Open-label	Germany, Japan, USA	DES	PTA or BMS	241	238	ZILVER-PTX Stent by COOK Medical	3
THUNDER [24, 47]	NCT00156624	5	Multi-center; Single-blind	Germany	DCB	PTA	48	54	Cotavance Balloon by Bavaria Medizin	3
IN.PACT SFA [6, 32, 39]	NCT01175850	5	Multi-center; Single-blind	Germany	DCB	PTA	220	111	IN.PACT Admiral Balloon by Medtronic	3.5
	NCT01566461
FEMPAC [44]	NCT00472472	2	Multi-center; Single-blind	Germany	DCB	PTA	45	42	Paccocath Balloon by Bavaria Medizin	3
LEVANT I [46]	NCT00930813	2	Multi-center; Single-blind	Belgium, Germany	DCB	PTA	49	52	Lutonix Balloon by CR BARD	2
LEVANT II [26, 72]	NCT01412541	5	Multi-center; Single-blind	Belgium, Germany, USA	DCB	PTA	316	160	Lutonix Balloon by CR BARD	2
ILLUMENATE EU [43, 49, 70]	NCT01858363	5	Multi-center; Single-blind	Austria, Germany	DCB	PTA	222	72	Stellarex Balloon by Spectranetics	2
CONSEQUENT [23, 74]	NCT01970579	2	Multi-center; Single-blind	Germany	DCB	PTA	78	75	SeQuent Please Balloon By B.Braun Melsungen AG	3
ISAR-STATH [62]	NCT00986752	2	Two-center; Open-label	Germany	DCB+BMS	PTA+BMS	48	52	IN.PACT Admiral Balloon by Medtronic	3.5
ISAR-PEBIS [45]	NCT01083394	2	Two-center; Open-label	Germany	DCB	PTA	36	34	IN.PACT Admiral Balloon by Medtronic	3.5
IN.PACT SFA JAPAN [33, 34]	NCT01947478	2	Multi-center; Single-blind	Japan	DCB	PTA	68	32	IN.PACT Admiral Balloon by Medtronic	3.5
ACOART I [22, 29, 48]	NCT01850056	5	Multi-center; Single-blind	China	DCB	PTA	100	100	Orchid Balloon by Acotec Scientific	3
FINN-PTX [37]	NCT01450722	2	Multi-center; Open-label	Finland	DES	PTFE Bypass Graft	23	18	ZILVER-PTX Stent by COOK Medical	3
BATTLE [61]	NCT02004951	2	Multi-center; Open-label	France	DES	BMS	86	85	ZILVER-PTX Stent by COOK Medical	3
DEBATE-IN-SFA [38]	UMIN000010071	1	Multi-center; Open-label	Japan	DES	BMS	85	85	ZILVER-PTX Stent by COOK Medical	3
DEBELLUM [27]	NA	1	Single-center; Open-label	Italy	DCB	PTA	25	25	IN.PACT Admiral Balloon by Medtronic	3.5
PACIFIER [57, 75]	NCT01083030	2	Multi-center; Single-blind	Germany	DCB	PTA	44	47	IN.PACT Pacific Balloon by Medtronic	3.5
FAIR [31]	NCT01305070	1	Multi-center; Single-blind	Germany	DCB	PTA	62	57	IN.PACT Admiral Balloon by Medtronic	3.5
BIOLUX P-I [60]	NCT01056120	1	Multi-center; Single-blind	Austria,Belgium,France,Germany,Ireland,Israel,Latvia,Netherlands,Spain,Switzerland	DCB	PTA	30	30	Passeo-18 Lux Balloon by Biotronik	3
RANGER SFA [21, 69]	NCT02013193	1	Multi-center; Single-blind	Austria,France,Germany	DCB	PTA	71	34	Ranger Balloon by Boston Scientific	2
ILLUMENATE pivotal [43, 54, 68]	NCT01858428 NCT01912937	5	Multi-center; Single-blind	USA	DCB	PTA	200	100	Stellarex Balloon by Spectranetics	2
DEBATE-SFA [36]	NCT01556542	1	Single-center; Open-label	Italy	DCB+BMS	PTA+BMS	53	51	IN.PACT Admiral Balloon by Medtronic	3.5
LEVANT JAPAN [50, 66]	NCT01816412	2	Multi-center; Single-blind	Japan	DCB	PTA	71	38	Lutonix Balloon by CR BARD	2
RAPID [28, 67]	ISRCTN47846578	2	Multi-center; Double-blind	Netherlands	DCB+BMS	PTA+BMS	80	80	Legflow Balloon by Cardionovum	3
EFFPAC [30, 41, 53]	NCT02540018	2	Multi-center; Single-blind	Germany	DCB	PTA	85	86	Luminor-35 Balloon by iVascular	3
PACUBA [58]	NCT01247402	1	Two-center; Single-blind	Austria	DCB	PTA	35	39	FREEWAY Balloon by Eurocor	3
FREEWAY [64]	NCT01960647	1	Multi-center; Single-blind	Austria,Germany	DCB+BMS	PTA+BMS	105	99	FREEWAY Balloon by Eurocor	3
DRECOREST [35]	NCT03023098	1	Single-center; Double-blind	Finland	DCB	PTA	29	28	IN.PACT Balloon by Medtronic	3.5
SWEDEPAD [10]	NCT02051088	2.49 (Mean, Ongoing)	Multi-center; Open-label	Sweden	DCB	PTA	1149	1140	Multiple device bands	NA
Falkowski et al. [25]	NA	3	Single-center; NA	Poland	DES	BMS	126	130	Zilver PTX Stent by Cook Medical	3
COPA CABANA [56]	NCT01594684	2	Multi-center; Double-blind	Germany	DCB	PTA	47	41	Cotavance Balloon by MEDRAD	3
Liao et al. [63]	ChiCTR1800017055	1	Single-center; Single-blind	China	DCB	PTA	38	36	Orchid Balloon by Acotec Scientific	3
RANGER II SFA [19, 20]	NCT03064126	1	Multi-center; Single-blind	Austria,Belgium,Canada,Japan,New Zealand,USA	DCB	PTA	278	98	Ranger Balloon by Boston Scientific	2
BIOPAC [51]	NCT02145065	3	Multi-center; Single-blind	Poland	DCB	PTA	33	33	Microcrystalline PAK Balloon by Balton Sp. z o.o., Warszawa, Poland	3
Ni et al. [52]	NCT03844724	1	Multi-center; Single-blind	China	DCB	PTA	93	99	ZENFlow Balloon by Zylox Medical Device Inc	3
ORCHID CHINA [55]	ChiCTR1900023619	1	Single-center; Single-blind	China	DCB	PTA	30	30	Orchid Balloon by Acotec Scientific	3
Ye et al. [65]	NA	2	Multi-center; Open-label	China	DCB	PTA	100	100	Reewarm™ PTX by Endovastec Co., Ltd	3
FREEWAY-CHINA [73]	NA	1	Multi-center; Open-label	China	DCB	PTA	155	154	FREEWAY Balloon by Eurocor	3
EMINENT [42]	NCT02921230	1	Multi-center; Single-blind	Austria,Belgium,France,Germany,Ireland,Italy,Netherlands,Spain,Switzerland,UK	DES	BMS	508	267	ELUVIA Stent by Boston Scientific	0.167

BMS: bare metal stent; DCB: drug-coated balloon; DES: drug-eluting stent; PTA: percutaneous transluminal angioplasty

There were three 3-arm RCTs (DEBATE-IN-SFA [38], ISAR-STATH [62] and THUNDER [24, 47]) and only patients receiving the paclitaxel DCB/DES and standard PTA/BMS were included in the meta-analysis, while observations from the BMS plus cilostazol (DEBATE-IN-SFA), directional atherectomy (ISAR-STATH) and PTA plus paclitaxel in the contrast medium (THUNDER) groups were removed. In the ZILVER-PTX trial, patients assigned to the PTA arm through the primary randomization underwent a secondary randomization to DES or BMS if PTA failed acutely [40, 59, 71] and we pooled the results of patients receiving DES during both randomizations in the analysis.

The average age was over 65 years in all studies and about 65% of patients were male. The number of patients with IC and CLTI at baseline based on the Rutherford classification was reported in 37 RCTs. In total, 2342 (29%) patients had CLTI and 5729 (71%) had IC. The majority of patients in the DEBATE-SFA [36], SWEDEPAD [10] and Ni et al. [52] trials had CLTI, and in 28 RCTs, IC only accounted for less than 20% of enrolled patients. The detailed demographic and angiographic characteristics at baseline of the included RCTs can be found in S2 and S3 Tables, respectively. All-cause mortality data at one, two and five years are shown in S4 Table.

All the included 39 RCTs were judged to be of high overall risk of bias and the main source of risk arose from the bias due to deviations from intended interventions. There existed noticeable visual difference between paclitaxel-coated/eluting devices and standard uncoated devices. Therefore, investigators were usually not blinded to treatment assignment, which might affect the clinical decision making during the follow-up period. Detailed risk of bias assessment for each included RCT is presented in S1 Fig.

All-cause mortality

The one-year all-cause mortality was reported in all 39 RCTs with 8990 patients. The crude risk of death at one year was 4.3% (214/5025) in the paclitaxel arm and 4.5% (177/3965) in the control arm. As shown in Fig 2, the random-effects model yielded a pooled RR of 1.06 (95% CI [0.87, 1.29]), suggesting no statistically significant difference in one-year mortality between the paclitaxel DCB/DES and control groups. There was no heterogeneity across the studies (I2 = 0%; p = 0.98).

Fig 2

Forest plot of all-cause mortality at one year.

RR is the risk ratio and CI represents the 95% confidence interval.

A total of 26 RCTs directly recorded all-cause deaths by two years. The unplanned interim analysis of SWEDEPAD trial [10] reported safety outcomes of paclitaxel-coated devices during a mean follow-up of 2.5 years. We estimated the number of deaths by two years in the SWEDEPAD trial [10] using the two-year cumulative incidence rate multiplied with the total number of patients in each group. Overall, at the two-year follow-up, 382 out of 3788 patients (10.1%) in the paclitaxel arm and 299 out of 2955 patients (10.1%) in the control arm had died. The forest plot in Fig 3 indicates that the use of paclitaxel-coated/eluting devices in the FPAs tended to increase the risk of death at two years but the evidence was not statistically significant (the random-effects model yielded RR = 1.08, 95% CI [0.93, 1.25]). We observed no heterogeneity among these 26 RCTs (I2 = 0%; p = 0.47).

Fig 3

Forest plot of all-cause mortality at two years.

RR is the risk ratio and CI represents the 95% confidence interval.

The five-year all-cause mortality was available only from eight RCTs with 2165 patients. The crude all-cause mortality at five years was 18.2% (247/1360) for patients receiving paclitaxel-coated/eluting devices and 15.2% (122/805) for those in the control group. The pooled RR calculated from the random-effects model was 1.18 (95% CI [0.92, 1.51]) (Fig 4). Although there was a 3.0% difference in the crude five-year mortality rate (95% CI [-0.2%, 6.2%]) between the paclitaxel-coated/eluting devices and control groups, the meta-analysis suggested that use of paclitaxel-coated balloons and stents did not significantly increase the risk of death during the five-year follow-up period. No heterogeneity was found among these eight RCTs (I2 = 28%; p = 0.20).

Fig 4

Forest plot of all-cause mortality at five years.

RR is the risk ratio and CI represents the 95% confidence interval.

Subgroup and sensitivity analysis

Subgroup analyses were performed to verify the influence of different paclitaxel interventions (DCB, DES or DCB+BMS) and dose levels (2.0, 3.0, 3.5μg/mm2 stents or balloons) on all-cause mortality. We only analyzed subgroups with more than three RCTs. In subgroup analysis concerning different types of paclitaxel interventions, patients treated with DES had relatively higher one-year mortality rates compared with the control and in all intervention subgroups there was no significant difference in the risk of deaths at one, two and five years between the paclitaxel and control arms (Table 2). With respect to subgroup analysis of paclitaxel doses, studies using 3.5μg/mm2 DCB showed a higher RR (the random-effects model yielded RR = 2.77, 95% CI [0.84, 9.22]) of two-year all-cause deaths compared to those using lower dose balloons and stents, while for all dose levels, no statistically significant result was found under the random-effects model.

Table 2

Subgroup analyses of all-cause mortality with subgroups including more than three randomized controlled trials.

		Risk Ratio (95% CI)
	Period	Random-effects	Fixed-effects
Paclitaxel intervention
DCB	1 year	1.02 (0.83, 1.26)	1.01 (0.82, 1.24)
DCB	2 years	1.06 (0.91, 1.23)	1.08 (0.93, 1.26)
DCB	5 years	1.12 (0.86, 1.48)	1.15 (0.92, 1.43)
DES	1 years	1.71 (0.83, 3.51)	1.79 (0.89, 3.59)
DES	2 years	1.09 (0.41, 2.94)	1.11 (0.61, 2.01)
DCB+BMS	1 year	1.07 (0.30, 3.76)	1.10 (0.36, 3.35)
Dose level
2.0μg/mm2 DCB	1 year	0.90 (0.47, 1.74)	0.92 (0.48, 1.75)
2.0μg/mm2 DCB	2 years	1.05 (0.69, 1.58)	1.07 (0.71, 1.61)
3.0μg/mm2 DES	1 year	1.43 (0.59, 3.48)	1.53 (0.66, 3.54)
3.0μg/mm2 DES	2 years	1.09 (0.41, 2.94)	1.11 (0.61, 2.01)
3.0μg/mm2 DCB	1 year	0.94 (0.55, 1.63)	0.89 (0.54, 1.48)
3.0μg/mm2 DCB	2 years	0.86 (0.56, 1.33)	0.85 (0.56, 1.29)
3.5μg/mm2 DCB	1 year	1.42 (0.60, 3.40)	1.35 (0.63, 2.90)
3.5μg/mm2 DCB	2 years	2.77 (0.84, 9.22)	3.05 (1.33, 7.01)

BMS: bare metal stent; CI: confidence interval; DCB: drug-coated balloon; DES: drug-eluting stent.

We conducted sensitivity analyses using the fixed-effects model, various continuity correction methods for rare events and the Bayesian binomial-logit model on arm-level observations. We also considered exclusion of SWEDEPAD trial in the two-year meta-analysis because the data were estimated from the survival curves. As shown in S5 Table, in all cases the pooled estimate was close to that in the primary analysis and there was still no statistically significant increase of all-cause mortality due to the use of paclitaxel.

In addition, we conducted cumulative meta-analysis by years of publications on the two- and five-year all-cause mortality as a post-hoc analysis and the estimates from the random-effects model were shown in Fig 5 and S6 Table. For each follow-up period, the sequential plot started from the year in which ≥3 RCTs reported the endpoint of interest. As shown in Fig 3, for the 2-year all-cause mortality, studies in Katasanos et al. [7] reported an RR of 1.64 (95% CI [1.12, 2.40]) while the newly added studies yielded an RR of 1.00 (95% CI [0.86; 1.17]), which delivered contradictory results. The difference in the two-year all-cause mortality was statistically significant only in 2018 (RR = 1.51, 95% CI [1.05, 2.17] from 12 RCTs), and the two-year RR had been falling since 2017. Four RCTs (IN.PACT SFA [6], LEVANT II [26], THUNDER [24] and ZILVER-PTX [40]) reported five-year all-cause deaths by 2019, which yielded a pooled RR of 1.61 (95% CI [1.20, 2.16]). However, the pooled results turned to be insignificant after inclusion of four newly published RCTs (ACOART I [48], ILLUMENATE EU, ILLUMENATE pivotal [43] and EFFPAC [53]) in 2021 and 2022.

Fig 5

Cumulative pooled treatment effect estimates (the logarithm of risk ratio) from the random-effects model by years of publications.

Publication bias

Visual inspection of funnel plots (S2 Fig) suggested no publication bias at one, two and five years due to approximately symmetrical shapes, and Egger’s test produced confirmative results (one-year, p = 0.87; two-year, p = 0.82; five-year, p = 0.89), see S7 Table.

Discussion

This systematic review and meta-analysis evaluated safety of the use of paclitaxel-coated/eluting devices in the FPAs and showed no significant difference in either short- or long-term all-cause mortality between patients receiving paclitaxel DCBs/DESs and those receiving the control (one-year RR, 1.06, 95% CI [0.87, 1.29]; two-year RR 1.08, 95% CI [0.93, 1.25]; five-year RR 1.18, 95% CI [0.92, 1.51]). Our findings are contrary to the results in Katsanos et al. [7] published in 2018, which reported significant mortality signals at two and five years due to paclitaxel usage. Compared with previous meta-analyses, our study included more recently published RCTs after 2020 and we can further investigate the trend of the increased risk of death due to paclitaxel over the publication time. The cumulative meta-analysis by years of publications (Fig 5) demonstrated that the inclusion of the most recently published studies reduced the difference in mortality between the paclitaxel and control arms and thus led to insignificant pooled results. For several recent studies, e.g., BATTLE (2-year) [61], COPA CABANA (2-year) [56], EFFPAC (2-year, 5-year) [30, 53], ACOART I (5-year) [48], patients in the control arm even had a higher risk of death compared with those receiving paclitaxel interventions. Pooled estimates from the meta-analysis are consistent across various statistical methods in the sensitivity analysis. The subgroup of the high paclitaxel dose (3.5μg/mm2) showed a potential tendency towards a higher risk of death at one and two years compared with the low-dose one. No publication bias existed at any of the investigated follow-up periods.

The controversial meta-analysis of Katsanos et al. [7] has provoked heated discussions and debates worldwide on the long-term safety of paclitaxel-delivery devices in treating PAD. Subsequently, multiple studies were performed based on different data sources and statistical models, which repeatedly identified the late mortality signal. As a result, the US FDA released three warning letters and also conducted a preliminary analysis for the FDA-approved paclitaxel-coated devices, which confirmed the finding of an increased mortality rate due to the use of paclitaxel up to five years (RR = 1.72, 95% CI [1.25, 2.38]), but no significant difference was found in the two-year mortality (RR = 1.31, 95% CI [0.76, 2.29]) [8, 9, 26]. A Bayesian meta-analysis [76] identified only a borderline difference in mortality between paclitaxel and control arms beyond two years with inconclusive evidence. To overcome the lack of access to the original patient-level data, Albrecht et al. [75] and the Vascular Interventional Advances (VIVA) group [77] performed individual-patient-data meta-analyses based on patient-level data of four and eight RCTs, respectively. Albrecht et al. [75] indicated no evidence of increased risk of death using paclitaxel interventions at two years. The VIVA group reported a hazard ratio of 1.38 (95% CI [1.06, 1.80]) during a median follow-up of four years [77]. Klumb et al. [5] conducted a meta-analysis which included studies before February 2019 to evaluate the influence of paclitaxel-coated balloon angioplasty for patients with FPA diseases and they found no evidence on the increased risk of the two-year all-cause mortality after DCB. Based on individual patient-level data from two single-arm trials and two RCTs, Schneider et al. [78] demonstrated the safety of the use of paclitaxel-coated balloons to treat FPA diseases. An updated meta-analysis conducted by Dinh et al. [79] identified 34 RCTs before December 2020 and reported no association between the increased risk of all-cause mortality and the implementation of paclitaxel devices. Mathlouthi et al. [80] performed a retrospective study on patients receiving paclitaxel-eluting stents and claimed no difference in the 2-year all-cause mortality in the real-world setting. Nevertheless, they observed a significantly higher risk of death among patients who required longer stents and higher paclitaxel doses. In addition, several retrospective cohort studies using large real-world datasets [81-84] were conducted to investigate safety outcomes of paclitaxel-coated devices while the late mortality signal could not be detected in any of these studies.

In conclusion, we observed no association between increased risk of death and the use of paclitaxel while with a longer follow-up period, the pooled results yielded a higher estimate of RR for paclitaxel versus control. On the other hand, paclitaxel DCBs and DESs have shown superiority over the standard uncoated endovascular therapies in reducing restenosis, target lesion revascularization and improving the quality of life. Considering the trustworthy clinical effectiveness and potential long-term risk, the risk-benefit profiles of paclitaxel DCBs and DESs are still of uncertainty. In real clinical practice, it is suggested to assess whether the treatment benefit of using paclitaxel in balloons and stents could outweigh the risk of mortality for each individual patient [8, 9, 69, 81].

As an update of the work by Katsanos et al. [7], this study has several limitations. The entire analysis was performed on the aggregate-level data. In the presence of censoring, survival analysis on time-to-event observations would be more appropriate, while for most of the included RCTs we had no access to individual patient data and the summarized binary data were used instead. When counting the number of patients, we excluded patients who were lost to follow-up to alleviate potential bias. Without the original patient-level data, we were unable to investigate the relationship between patient characteristics and survival or explore undetected sources of clinical heterogeneity. Most of the included RCTs focused on the evaluation of benefits of paclitaxel-coated devices (e.g., patency, late lumen loss, restenosis) and mortality was not the primary endpoint used for the trial design.

In the cumulative meta-analysis by years of publications, we observed a decreasing trend of RR for the two- and five-year all-cause mortality, indicating that paclitaxel-coated/eluting devices implemented in recent years were less toxic to patients with PAD. The improvement of products using paclitaxel might make substantial contributions to the treatment of lesions in the femoropopliteal arteries. However, in this study we did not consider this issue since there were few studies investigating the efficacy and safety of a specific paclitaxel device and the corresponding subgroup analysis could not provide convincing evidence. We focused on the use of paclitaxel-coated/eluting devices in FPA and excluded RCTs for infrapopliteal artery diseases. The safety of paclitaxel exposure in below-the-knee arteries is also a controversial topic [85] and several meta-analyses have been conducted [86-88]. Another limitation of our study is that we only considered a single safety endpoint of all-cause mortality and did not examine the association between the use of paclitaxel and other safety outcomes, e.g., thrombosis, allergy and major amputation of the target limb.

Conclusion

This systematic review and summary-level meta-analysis showed that the use of paclitaxel DCBs and DESs was not associated with the increased short- or long-term mortality. Concerning well-proven clinical effectiveness of paclitaxel devices in the femoropopliteal arteries, further investigations including more RCTs with longer follow-up periods and individual patient-level data are warranted to shed more light on the risk-benefit profiles of paclitaxel usage in PAD patients.

Risk of bias assessment.

(TIF)

Click here for additional data file.

Funnel plots at (a) one year; (b) two years; (c) five years.

(TIF)

Click here for additional data file.

Search strategy of online databases.

(DOCX)

Click here for additional data file.

Detailed demographic statistics of included randomized controlled trials.

(DOCX)

Click here for additional data file.

Detailed angiographic statistics of included randomized controlled trials.

(DOCX)

Click here for additional data file.

All-cause mortality at one, two and five years of included randomized controlled trials.

(DOCX)

Click here for additional data file.

Sensitivity analyses of all-cause mortality.

Risk ratio (95% CI) for frequentist methods and odds ratio (95% equal-tailed CrI) for Bayesian methods.

(DOCX)

Click here for additional data file.

Cumulative meta-analysis by year of publication.

(DOCX)

Click here for additional data file.

Egger’s test of publication bias.

(DOCX)

Click here for additional data file.

(DOCX)

Click here for additional data file.

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

21 Jun 2022

Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis

PLOS ONE

Dear Dr. Yin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers raised a number of concerns with your manuscript, including the methodological approach and the rationale for the study in the context of existing work, and the presentation of your data. The reviewers' comments can be viewed in full, below.

Please submit your revised manuscript by Jul 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Natasha McDonald, PhD

Associate Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please upload a new copy of Figure S1 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I would like to congratulate authors on this important manuscript. It well written manuscript with crucial implications in PAD. I agree with the findings as paclitaxel coated has no impact on patient mortality.

However to further strengthen the manuscript I would recommend following.

1. Please provide the location data on each study including countries where patients were enrolled.

2. Please provide the data on patient demographic and clinical characteristics if available.

3. As prior meta analysis has shown similar results, should include in more detail the novelty of this study ( mathlouthi et al journal of vascular surgery feb 2021, P Schneider et al May 2109 JACC)

4. Please include more limitations of the study.

Reviewer #2: The artile is technically good, but I'm affraid that the results are expect after the publication of the SWEDPAD study. Therefore, as it is written, the study adds little to the current evidence. However, it could be improved if the authors organized the way they present the results.

This study is not novel but it can help to understand what change in the risk estimation between 2018 (Katsanos) and 2022. Therefore, I suggest the authors that properly identify in their forest plots the new studies which have been published after 2018 so we identify them and understand their impact in the analysis. As you recognized in the discussion, being this an update of Katsanos, readers need to easily understand the differences between the works.

I saw you assessed the methodological quality of the studies using RoB 2 but you did not mention the results of the analysis in the results section. I suggest you do it.

"This systematic review and summary-level meta-analysis showed that the use of

paclitaxel DCBs and DESs was not associated with increased short- or long-term

mortality. However, at two and five years, we still observed a higher risk of death for

patients receiving paclitaxel-coated/eluting devices and the meta-analysis yielded

marginal results yet reaching statistical significance." I dont agree with this conclusion. You demonstrated that no increased risk was found. You have wrote a discussion based on the absence of a statistically significant risk of death. But you contradict yourself regarding the risk of death in the conclusion section. I think this is not in line with your findings. so I suggest you to simplify the conclusion section based on your actual findings.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Sawan Jalnapurkar

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

17 Jul 2022

Responses to Comments from Reviewer 1 on Manuscript PONE-D-21-22189

We thank you for your careful review of our manuscript and many insightful comments. We have updated this meta-analysis and revised our manuscript by taking into account all of your comments, which led to a much better exposition of our work. Our point-by-point responses to major comments are given below, with your original comments copied in Italics for your convenience.

Comments:

1. Please provide the location data on each study including countries where patients were enrolled.

Response: Thanks for your suggestion. We have added the locations of the included randomized controlled trials (RCTs) in the revised Table 1.

2. Please provide the data on patient demographic and clinical characteristics if available.

Response: Thank you for this comment. We have added data on patient baseline demographic and angiographic characteristics of the included RCTs in S2 and S3 Tables (Supporting Information)

3. As prior meta analysis has shown similar results, should include in more detail the novelty of this study ( mathlouthi et al journal of vascular surgery feb 2021, P Schneider et al May 2109 JACC)

Response: Thank you for pointing out this issue. We added discussions on the comparisons between our meta-analysis and previous studies in the revised manuscript. The added text is quoted below.

Compared with previous meta-analyses, our study included more recently published RCTs after 2020 and we can further investigate the trend of the increased risk of death due to paclitaxel over the publication time.

……

Klumb et al. conducted a meta-analysis which included studies before February 2019 to evaluate the influence of paclitaxel-coated balloon angioplasty for patients with FPA diseases and they found no evidence on the increased risk of two-year all-cause mortality after DCB. Based on individual patient-level data from two single-arm trials and two RCTs, Schneider et al.demonstrated the safety of the use of paclitaxel-coated balloons to treat FPA diseases. An updated meta-analysis conducted by Dinh et al. identified 34 RCTs before December 2020 and reported no association between the increased risk of all-cause mortality and the implementation of paclitaxel devices. Mathlouthi et al. performed a retrospective study on patients receiving paclitaxel-eluting stents and claimed no difference in the 2-year all-cause mortality in the real-world setting. Nevertheless, they observed a significantly higher risk of death among patients who required longer stents and higher paclitaxel doses.

4. Please include more limitations of the study.

Response: Thank you for this suggestion. We discussed more limitations of our study in the Discussion section as follows.

In the cumulative meta-analysis by years of publications, we observed a decreasing trend of RR for the two- and five-year all-cause mortality, indicating that paclitaxel-coated/eluting devices implemented in recent years were less toxic to patients with PAD. The improvement of products using paclitaxel might make substantial contributions to the treatment of lesions in the femoropopliteal arteries. However, in this study we did not consider this issue since there were few studies investigating the efficacy and safety of a specific paclitaxel device and the corresponding subgroup analysis could not provide convincing evidence. We focused on the use of paclitaxel-coated/eluting devices in FPA and excluded RCTs for infrapopliteal artery diseases. The safety of paclitaxel exposure in below-the-knee arteries is also a controversial topic and several meta-analyses have been conducted. Another limitation of our study is that we only considered a single safety endpoint of all-cause mortality and did not examine the association between the use of paclitaxel and other safety issues, e.g., thrombosis, allergy and major amputation of the target limb.

Responses to Comments from Reviewer 2 on Manuscript PONE-D-21-22189

We thank you for your careful review of our manuscript and many insightful comments. We have updated this meta-analysis and revised our manuscript by taking into account all of your comments, which led to a much better exposition of our work. Our point-by-point responses to major comments are given below, with your original comments copied in Italics for your convenience.

Comments:

1. The article is technically good, but I'm afraid that the results are expect after the publication of the SWEDPAD study. Therefore, as it is written, the study adds little to the current evidence.

Response: Thanks for your comment. The SWEDEPAD trial enrolled 2289 patients and made an impactful contribution to the meta-analysis due to its large sample size. We agree that after the completion of the SWEDEPAD trial, the results of our meta-analysis might change. However, given the interim analysis of the SWEDEPAD trial, researches claimed that the results ‘did not show a difference between the groups in the incidence of death during 1 to 4 years of follow-up’, which is consistent with our conclusions. Given such an important controversial issue, our study gives a more comprehensive update of meta-analysis based on cumulative evidence. For this revision, ten new studies were added to our meta-analysis.

2. This study is not novel but it can help to understand what change in the risk estimation between 2018 (Katsanos) and 2022. Therefore, I suggest the authors that properly identify in their forest plots the new studies which have been published after 2018 so we identify them and understand their impact in the analysis. As you recognized in the discussion, being this an update of Katsanos, readers need to easily understand the differences between the works.

Response: Thanks for your suggestion. In Figs 2-4, we split all eligible RCTs into two subgroups: studies in Katsanos et al. and newly added studies. The revised forest plots show that for the 2-year all-cause mortality, studies in Katasanos et al. reported an RR of 1.64 (95% CI [1.12, 2.40]) while the newly added studies have an RR of 1.00 (95% CI [0.86; 1.17]), which delivers contradicted results. For the 5-year all-cause mortality , three studies in Katasanos et al. identified significantly increased risk of death due to the use of paclitaxel (RR=1.59, 95% CI [1.11, 2.29]]) while the five newly added studies demonstrated no association between the use of paclitaxel and increased risk of death (RR=1.01, 95% CI [0.75, 1.37]).

3. I saw you assessed the methodological quality of the studies using RoB 2 but you did not mention the results of the analysis in the results section. I suggest you do it.

Response: Thank you for this comment. We have added discussion on the evaluation of risk of bias as follows.

All the included 39 RCTs were judged to be of high overall risk of bias and the main source of risk arose from the bias due to deviations from intended interventions. There exists noticeable visual difference between paclitaxel-coated/eluting devices and standard uncoated devices. Therefore, investigators were usually not blinded to treatment assignment, which might affect the clinical decision making during the follow-up period. Detailed risk of bias assessment for each included RCT is presented in S1 Fig.

4. "This systematic review and summary-level meta-analysis showed that the use of paclitaxel DCBs and DESs was not associated with increased short- or long-term mortality. However, at two and five years, we still observed a higher risk of death for patients receiving paclitaxel-coated/eluting devices and the meta-analysis yielded marginal results yet reaching statistical significance." I dont agree with this conclusion. You demonstrated that no increased risk was found. You have wrote a discussion based on the absence of a statistically significant risk of death. But you contradict yourself regarding the risk of death in the conclusion section. I think this is not in line with your findings. so I suggest you to simplify the conclusion section based on your actual findings.

Response: Thank you for pointing out this issue. We have revised this part in the revised manuscript as follows.

However, at two and five years, we observed a potential tendency yet reaching statistical significance towards increased risk of death for patients receiving paclitaxel-coated/eluting devices. Concerning well-proven clinical effectiveness of paclitaxel devices in the femoropopliteal arteries, further investigations including more RCTs with longer follow-up periods and individual patient-level data are warranted to shed more light on the risk-benefit profiles of paclitaxel usage in PAD patients.

2 Sep 2022

5 Sep 2022

We thank you for your careful review of our manuscript and many insightful comments. We have revised our manuscript by considering all of your comments, which led to a much better exposition of our work. Our point-by-point responses to major comments are given below, with your original comments copied in Italics for your convenience.

Comments:

To Editor:

1. In particular, carefully revise the tone of the discussion to accommodate the recommendations by Reviewer #3.

Response: Thanks for your suggestion. We have revised the mentioned sentences in the Abstract and Discussion sections following the recommendations by Reviewer #3.

To Reviewer #3

1. I suggest to re-consider the sentences were a trend towards increased risk of death is highlighted, since this is not strongly supported by the findings, especially when looking at more recently published RCTs (after 2020).

Response: Thank you for pointing out this problem. In the revised manuscript we have modified sentences involving ‘a trend towards increased risk of death’ in the Abstract and Discussion sections.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

26 Sep 2022

Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis

PONE-D-21-22189R2

Dear Dr. Yin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Salvatore De Rosa

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors have amended the manuscript according to the criticism raised. I have no further comments

Reviewers' comments:

2 Oct 2022

PONE-D-21-22189R2

Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis

Dear Dr. Yin:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Salvatore De Rosa

Academic Editor

PLOS ONE